stocks logo

TVTX Valuation

Travere Therapeutics Inc
$
18.230
+0.18(0.997%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

TVTX Relative Valuation

TVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TVTX is overvalued; if below, it's undervalued.

Historical Valuation

Travere Therapeutics Inc (TVTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.24 is considered Undervalued compared with the five-year average of 3.33. The fair price of Travere Therapeutics Inc (TVTX) is between 109.71 to 127.21 according to relative valuation methord. Compared to the current price of 18.19 USD , Travere Therapeutics Inc is Undervalued By 83.42%.
Relative Value
Fair Zone
109.71-127.21
Current Price:18.19
83.42%
Undervalued
243.92
PE
1Y
3Y
5Y
Trailing
Forward
17.81
EV/EBITDA
Travere Therapeutics Inc. (TVTX) has a current EV/EBITDA of 17.81. The 5-year average EV/EBITDA is 12.16. The thresholds are as follows: Strongly Undervalued below -144.60, Undervalued between -144.60 and -66.22, Fairly Valued between 90.54 and -66.22, Overvalued between 90.54 and 168.92, and Strongly Overvalued above 168.92. The current Forward EV/EBITDA of 17.81 falls within the Historic Trend Line -Fairly Valued range.
-40.16
EV/EBIT
Travere Therapeutics Inc. (TVTX) has a current EV/EBIT of -40.16. The 5-year average EV/EBIT is -6.91. The thresholds are as follows: Strongly Undervalued below -17.99, Undervalued between -17.99 and -12.45, Fairly Valued between -1.36 and -12.45, Overvalued between -1.36 and 4.18, and Strongly Overvalued above 4.18. The current Forward EV/EBIT of -40.16 falls within the Strongly Undervalued range.
3.26
PS
Travere Therapeutics Inc. (TVTX) has a current PS of 3.26. The 5-year average PS is 5.39. The thresholds are as follows: Strongly Undervalued below 1.49, Undervalued between 1.49 and 3.44, Fairly Valued between 7.34 and 3.44, Overvalued between 7.34 and 9.29, and Strongly Overvalued above 9.29. The current Forward PS of 3.26 falls within the Undervalued range.
-21.01
P/OCF
Travere Therapeutics Inc. (TVTX) has a current P/OCF of -21.01. The 5-year average P/OCF is -10.69. The thresholds are as follows: Strongly Undervalued below -28.72, Undervalued between -28.72 and -19.71, Fairly Valued between -1.68 and -19.71, Overvalued between -1.68 and 7.34, and Strongly Overvalued above 7.34. The current Forward P/OCF of -21.01 falls within the Undervalued range.
13.41
P/FCF
Travere Therapeutics Inc. (TVTX) has a current P/FCF of 13.41. The 5-year average P/FCF is -6.50. The thresholds are as follows: Strongly Undervalued below -33.69, Undervalued between -33.69 and -20.09, Fairly Valued between 7.10 and -20.09, Overvalued between 7.10 and 20.69, and Strongly Overvalued above 20.69. The current Forward P/FCF of 13.41 falls within the Overvalued range.
Travere Therapeutics Inc (TVTX) has a current Price-to-Book (P/B) ratio of 47.37. Compared to its 3-year average P/B ratio of 13.01 , the current P/B ratio is approximately 264.19% higher. Relative to its 5-year average P/B ratio of 9.87, the current P/B ratio is about 379.99% higher. Travere Therapeutics Inc (TVTX) has a Forward Free Cash Flow (FCF) yield of approximately -7.50%. Compared to its 3-year average FCF yield of -26.26%, the current FCF yield is approximately -71.42% lower. Relative to its 5-year average FCF yield of -16.80% , the current FCF yield is about -55.33% lower.
49.11
P/B
Median3y
13.01
Median5y
9.87
-7.45
FCF Yield
Median3y
-26.26
Median5y
-16.80

Competitors Valuation Multiple

The average P/S ratio for TVTX's competitors is 88.00, providing a benchmark for relative valuation. Travere Therapeutics Inc Corp (TVTX) exhibits a P/S ratio of 3.26, which is -96.29% above the industry average. Given its robust revenue growth of 111.49%, this premium appears sustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of TVTX increased by 92.50% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 54.12M to 114.45M.
The secondary factor is the P/E Change, contributed 72.35%to the performance.
Overall, the performance of TVTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
111.49%
54.12M → 114.45M
Revenue Growth
+
-91.34%
-128.71 → -11.14
Margin Expansion
+
72.35%
-5.24 → -9.03
P/E Change
=
92.50%
9.47 → 18.23
Mkt Cap Growth

FAQ

arrow icon

Is Travere Therapeutics Inc (TVTX) currently overvalued or undervalued?

Travere Therapeutics Inc (TVTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.24 is considered Undervalued compared with the five-year average of 3.33. The fair price of Travere Therapeutics Inc (TVTX) is between 109.71 to 127.21 according to relative valuation methord. Compared to the current price of 18.19 USD , Travere Therapeutics Inc is Undervalued By 83.42% .
arrow icon

What is Travere Therapeutics Inc (TVTX) fair value?

arrow icon

How does TVTX's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Travere Therapeutics Inc (TVTX) as of Aug 15 2025?

arrow icon

What is the current FCF Yield for Travere Therapeutics Inc (TVTX) as of Aug 15 2025?

arrow icon

What is the current Forward P/E ratio for Travere Therapeutics Inc (TVTX) as of Aug 15 2025?

arrow icon

What is the current Forward P/S ratio for Travere Therapeutics Inc (TVTX) as of Aug 15 2025?